发明名称 STABILIZED FACTOR IX FORMULATIONS CONTAINING TREHALOSE
摘要 Methods of preparing lyophilized preparations of Factor IX which preserve more than 90% of the calcium binding property of Factor IX are disclosed. Factor IX formulated with trehalose shows a superior stability profile after 12 weeks storage at 25° C./60% relative humidity (RH) and 40° C./75% RH relative to Factor IX formulated without trehalose. The data suggest that the inclusion of trehalose in the formulation could allow for temperature excursions or even long-term room temperature storage of a Factor IX lyophilized product. The formulations tested contained 10 mM histidine pH 6.8, 3% mannitol, 66 mM sodium chloride, 0.0075% Polysorbate 80, with and without 1% trehalose. Upon storage at 40° C./75% RH or 25° C./60% RH over 12 weeks the trehalose-containing formulation was comparable to product stored at 2-8° C. while the formulation without trehalose was found to undergo significant aggregation and loss of activity. The two formulations demonstrated comparable stability over 26 weeks of real time storage at −20° C. and 2-8° C.
申请公布号 US2016287709(A1) 申请公布日期 2016.10.06
申请号 US201514879310 申请日期 2015.10.09
申请人 CNJ Holdings, Inc. 发明人 Mankarious Samia;Griffith Michael J.
分类号 A61K47/36;A61K38/48 主分类号 A61K47/36
代理机构 代理人
主权项
地址 Winnipeg CA